Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T7OI
|
|||
| Drug Name |
Anti-LAG3
|
|||
| Indication | Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 2 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 2 | [1] | ||
| Company |
Bristol-Myers Squibb Princeton, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation gene 3 protein (LAG3) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.